Cautious optimism in anticipation of hepatitis B curative therapies  

作　　者：Alla Turshudzhyan Micheal Tadros 

机构地区：[1]Department of Medicine,University of Connecticut,Farmington,CT 06030-1235,United States [2]Department of Gastroenterology and Hepatology,Albany Medical College,Albany,NY 12208,United States

出　　处：《World Journal of Virology》2022年第4期212-215,共4页世界病毒学杂志

摘　　要：Despite relative effectiveness of current hepatitis B therapies,there is still no curative agents available.The new emerging approaches hold promise to achieve cure and loss of hepatitis B surface antigen.Studies or clinical trials investigating new therapies remain small and either focus on patients with low viral load and without hepatotoxic injury or patients with hepatitis D co-infection,which makes it challenging to assess their effectiveness and side effect profile in hepatitis B population.

关 键 词：Hepatitis B Hepatitis B virus Hepatitis B virus entry inhibitor Bulevirtide Transcription activator-like effector nucleases Zinc-finger nucleases Clustered regularly interspaced short palindromic repeats-associated 9 Nucleocapsid assembly modulators Hepatitis B virus transcription inhibitors Hepatitis B surface antigen release inhibitors 

分 类 号：R51[医药卫生—内科学]